Aytu BioPharma Inc. (NASDAQ:AYTU) Given Consensus Recommendation of “Hold” by Analysts

Aytu BioPharma Inc. (NASDAQ:AYTU) has received a consensus rating of “Hold” from the five analysts that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have assigned a buy recommendation to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $10.75.

A number of research analysts have commented on the stock. Citigroup reiterated a “positive” rating on shares of Aytu BioPharma in a research note on Tuesday. Zacks Research upgraded shares of Aytu BioPharma from a “strong sell” rating to a “hold” rating in a research report on Thursday, August 13th. Ascendiant Capital Markets lifted their price objective on shares of Aytu BioPharma from $14.00 to $14.50 and gave the company a “buy” rating in a research note on Thursday, June 11th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Aytu BioPharma in a research report on Monday, July 6th.

Aytu BioPharma Trading Up 4.7%

NASDAQ:AYTU traded up $0.10 during trading hours on Tuesday, reaching $2.23. 273,446 shares of the company were exchanged, compared to its average volume of 49,528. The firm has a market cap of $23.93 million, a price-to-earnings ratio of -0.49 and a beta of 0.26. The stock has a 50 day simple moving average of $2.21 and a 200 day simple moving average of $2.33. Aytu BioPharma has a 52-week low of $1.65 and a 52-week high of $3.07. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.12 and a quick ratio of 1.00.

Aytu BioPharma (NASDAQ:AYTU) last released its quarterly earnings data on Tuesday, September 22nd. The company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.24. Aytu BioPharma had a negative return on equity of 69.93% and a negative net margin of 60.17%.The business had revenue of $16.11 million during the quarter, compared to the consensus estimate of $12.28 million. As a group, analysts predict that Aytu BioPharma will post -0.73 EPS for the current year.

Hedge Funds Weigh In On Aytu BioPharma

Institutional investors have recently bought and sold shares of the stock. BlackRock Inc. purchased a new stake in Aytu BioPharma during the second quarter valued at about $49,000. Persistent Asset Partners Ltd purchased a new stake in shares of Aytu BioPharma in the 2nd quarter valued at approximately $82,000. Dimensional Fund Advisors LP boosted its stake in Aytu BioPharma by 23.3% in the 1st quarter. Dimensional Fund Advisors LP now owns 43,585 shares of the company’s stock worth $119,000 after purchasing an additional 8,222 shares during the period. Arete Wealth Advisors LLC purchased a new position in Aytu BioPharma during the 1st quarter worth approximately $135,000. Finally, Crown Advisors Management Inc. purchased a new position in Aytu BioPharma during the 2nd quarter worth approximately $430,000. Hedge funds and other institutional investors own 33.49% of the company’s stock.

About Aytu BioPharma

Aytu BioPharma, Inc is a specialty pharmaceutical company focused on commercializing prescription medicines, primarily for pediatric and primary-care markets. The company’s activities include acquiring, developing and commercializing products intended to address unmet needs in areas such as attention deficit hyperactivity disorder (ADHD), allergies and other common medical conditions.

Aytu’s ADHD portfolio has included Adzenys XR-ODT, an orally disintegrating extended-release amphetamine tablet; Cotempla XR-ODT, an orally disintegrating extended-release methylphenidate tablet; and Dyanavel XR, an extended-release liquid amphetamine formulation.